News and Announcements
TAIM Investments Monthly Performance Update: June 2018
- Published June 07, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
It was a tale of two halves on the Australian market this month, with the ASX200 performing strongly early to be up over +2% by the middle of the month, however, global jitters had their impact leading the ASX200 to close with a more modest gain of +0.5% for May. Our benchmark, the ASX200 Total Returns (including dividends), returned +1.1% for May, indicating a broader market gain of +8.5% during the period the TAIM Funds have been operating.
The TAIM Funds also gave up some of their strong initial gains late in the month, but still closed out May with solid returns, our Momentum Fund gaining +2.8% and our Leveraged Fund gaining +2.7% for the month. With investor returns of +17.6% and +19.8% respectively in their first 8 months, twice that of the general market, we are well on track to achieve our full year targets.
About TAIM Investments
TAIM Investments operates two Australian equities investment funds. Both have exhibited exceptional performance, during an initial 4-year small-scale-offering period, and now under the company’s own AFSL. Both funds have an Australian blue chip focus – portfolio of 20 ASX200 equities, long only, no short-selling or derivatives – and we use an automated quantitative approach to deliver superior performance.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
